

MAY 20 2004

K040575

**510 (k) SUMMARY  
AS REQUIRED BY SECTION 807.92(C)**

Identification: Moments Menopause Check (Models 9111 and 9112)

Description: Immunoassay for the qualitative detection FSH (follicle stimulating hormone) in urine

Name Of Manufacturer: Phamatech  
10151 Barnes Canyon Road  
San Diego, California 92121, USA

Intended Use: The Moments Menopause Check is a rapid, qualitative immunoassay for the detection of the FSH in urine. The minimum detectable concentration for this test is 25 mIU/ml. This assay is intended for use in the home to assist in the early detection of menopause.

Technology: The Moments Menopause Check, like many commercially available FSH screening test kits, qualitatively measures the presence of FSH by visual color sandwich one step immunoassay technology. Examples of such predicate devices include the Synova Menocheck and the Applied Biotech SureStep FSH (San Diego, CA 92121). All of the above devices rely on the basic immunochemical sandwich assay principle of recognition and formation of specific antibody / target analyte / antibody / complexes.

Performance: The product performance characteristics of the TBD Menopause Check were evaluated in a clinical sample correlation study and a blind labeled spiked study. The results of these studies demonstrate the Moments Menopause Check to be substantially equivalent to the reported performance characteristics of other commercially available tests for the qualitative detection of the FSH in urine. Laboratory studies, using clinical specimens, produced a 98% correlation when compared to the predicate devices. A consumer study was also performed. In it the Moments Menopause Check exhibited excellent overall accuracy (97%) in the hands of lay users.

Conclusion: For the reasons mentioned above, it may be concluded that the Phamatech Moments Menopause Check is substantially equivalent to a variety of detection tests currently in commercial distribution and is safe in the hands of the lay user.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration  
2098 Gaither Road  
Rockville MD 20850

**MAY 20 2004**

Mr. Carl A. Mongiovi  
Vice President  
Phamatech, Inc.  
10151 Barnes Canyon Road  
San Diego, CA 92121

Re: k040575  
Trade/Device Name: Moments Menopause Check (Models 9111 and 9112)  
Regulation Number: 21 CFR 862.1300  
Regulation Name: Follicle-stimulating hormone test system  
Regulatory Class: Class I  
Product Code: CGJ  
Dated: February 5, 2004  
Received: March 16, 2004

Dear Mr. Mongiovi:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of *In Vitro* Diagnostic Device Evaluation and Safety at (301) 594-3084. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>.

Sincerely yours,



Jean M. Cooper, MS, D.V.M.

Director

Division of Chemistry and Toxicology

Office of *In Vitro* Diagnostic Device

Evaluation and Safety

Center for Devices and

Radiological Health

Enclosure

## INDICATIONS FOR USE

Applicant: Phamatech

510 (k) Number (if known): **K040575**

Device Name: Moments Menopause Check (Models 9111 and 9112)

### Indications for Use:

The Moments Menopause Check is an in-vitro diagnostic screen for the detection of FSH (follicle stimulating hormone) in urine. Change in FSH levels may be associated with stages in menopause. This kit provides a preliminary result for the detection/presence of FSH in urine. It is intended for over-the-counter sales.

Prescription Use: \_\_\_\_\_  
Part 21 CFR 801 Subpart D

AND/OR

Over the Counter:  X   
21 CFR 807 Subpart C

---

Concurrence of CDRH Office of In Vitro Diagnostic Devices (OIVD)

Ruth Chisler For Carol Benion  
Division Sign-Off

Office of In Vitro Diagnostic Device  
Evaluation and Safety

510(k) 040575